BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 34715050)

  • 1. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
    Enshaei A; Vora A; Harrison CJ; Moppett J; Moorman AV
    Lancet Haematol; 2021 Nov; 8(11):e828-e839. PubMed ID: 34715050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.
    Moorman AV; Ensor HM; Richards SM; Chilton L; Schwab C; Kinsey SE; Vora A; Mitchell CD; Harrison CJ
    Lancet Oncol; 2010 May; 11(5):429-38. PubMed ID: 20409752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes).
    Heerema NA; Sather HN; Sensel MG; Zhang T; Hutchinson RJ; Nachman JB; Lange BJ; Steinherz PG; Bostrom BC; Reaman GH; Gaynon PS; Uckun FM
    J Clin Oncol; 2000 May; 18(9):1876-87. PubMed ID: 10784628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols.
    Paulsson K; Forestier E; Andersen MK; Autio K; Barbany G; Borgström G; Cavelier L; Golovleva I; Heim S; Heinonen K; Hovland R; Johannsson JH; Kjeldsen E; Nordgren A; Palmqvist L; Johansson B; ; ;
    Haematologica; 2013 Sep; 98(9):1424-32. PubMed ID: 23645689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia.
    Chessels JM; Swansbury GJ; Reeves B; Bailey CC; Richards SM
    Br J Haematol; 1997 Oct; 99(1):93-100. PubMed ID: 9359508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group.
    Forestier E; Johansson B; Gustafsson G; Borgström G; Kerndrup G; Johannsson J; Heim S
    Br J Haematol; 2000 Jul; 110(1):147-53. PubMed ID: 10930992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
    Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
    Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
    Parker C; Krishnan S; Hamadeh L; Irving JAE; Kuiper RP; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Moorman AV; Saha V
    Lancet Haematol; 2019 Apr; 6(4):e204-e216. PubMed ID: 30826273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
    Moorman AV; Robinson H; Schwab C; Richards SM; Hancock J; Mitchell CD; Goulden N; Vora A; Harrison CJ
    J Clin Oncol; 2013 Sep; 31(27):3389-96. PubMed ID: 23940220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
    Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
    Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol.
    Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S;
    Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
    Secker-Walker LM; Prentice HG; Durrant J; Richards S; Hall E; Harrison G
    Br J Haematol; 1997 Mar; 96(3):601-10. PubMed ID: 9054669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic significance of chromosome abnormalities in childhood acute lymphoblastic leukemia.
    Oláh E; Balogh E; Kajtár P; Pajor L; Jakab Z; Kiss C
    Ann N Y Acad Sci; 1997 Sep; 824():8-27. PubMed ID: 9382457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
    Hough R; Rowntree C; Goulden N; Mitchell C; Moorman A; Wade R; Vora A
    Br J Haematol; 2016 Feb; 172(3):439-51. PubMed ID: 26683485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia.
    Moorman AV; Richards SM; Martineau M; Cheung KL; Robinson HM; Jalali GR; Broadfield ZJ; Harris RL; Taylor KE; Gibson BE; Hann IM; Hill FG; Kinsey SE; Eden TO; Mitchell CD; Harrison CJ;
    Blood; 2003 Oct; 102(8):2756-62. PubMed ID: 12829593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aneuploidy in children with relapsed B-cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse.
    Groeneveld-Krentz S; Schroeder MP; Reiter M; Pogodzinski MJ; Pimentel-Gutiérrez HJ; Vagkopoulou R; Hof J; Chen-Santel C; Nebral K; Bradtke J; Türkmen S; Baldus CD; Gattenlöhner S; Haas OA; von Stackelberg A; Karawajew L; Eckert C; Kirschner-Schwabe R
    Br J Haematol; 2019 Apr; 185(2):266-283. PubMed ID: 30714092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL.
    Lee SHR; Ashcraft E; Yang W; Roberts KG; Gocho Y; Rowland L; Inaba H; Karol SE; Jeha S; Crews KR; Mullighan CG; Relling MV; Evans WE; Cheng C; Yang JJ; Pui CH
    J Clin Oncol; 2023 Dec; 41(35):5422-5432. PubMed ID: 37729596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.